Financial Data and Key Metrics Changes - For the full year, underlying sales growth was 3.5%, with volumes at 1.5% and price at 2% [5] - Turnover for the full year was EUR 50.5 billion, down 3.8% versus the prior year, primarily due to significant currency headwinds [25] - Underlying operating margin expanded by 60 basis points to 20% in 2025, reflecting a structurally strong margin profile [26] - Underlying EPS rose to EUR 3.08, up 0.7% versus the prior year, with sales growth and margin expansion contributing 6.5% to EPS growth [28] Business Line Data and Key Metrics Changes - Beauty and Wellbeing delivered underlying sales growth of 4.7% for the full year, with volumes up 2.8% [10] - Personal Care delivered underlying sales growth of 4.7% for the full year, driven by strong performance in the U.S. [11] - Home Care delivered underlying sales growth of 2.6% for the year, primarily volume-led at 2.2% [14] - Foods delivered underlying sales growth of 2.5% for the year, with 0.8% from volume and 1.7% from price [16] Market Data and Key Metrics Changes - Developed markets delivered underlying sales growth of 3.6% for the year, while emerging markets delivered underlying sales growth of 3.5% [19][21] - In North America, underlying sales grew 5.3% for the year, with volumes contributing 3.8% [20] - In Asia Pacific Africa, underlying sales growth was 4.6% for the year, with volumes contributing 3% [21] - Latin America saw underlying sales growth of 0.5% for the year, reflecting a broad-based market slowdown [23] Company Strategy and Development Direction - The company aims to focus on beauty, wellbeing, and personal care, with an emphasis on premium segments and digitally native brands [32][34] - The company completed the demerger of ice cream and 10 transactions to sharpen its portfolio and increase focus on growth [34] - The company is committed to a disciplined capital allocation strategy, focusing on growth and productivity while delivering attractive capital returns [31][44] Management's Comments on Operating Environment and Future Outlook - The management expressed confidence in emerging markets, expecting volume growth of at least 2% in 2026 [36] - The company anticipates underlying sales growth for 2026 to be at the bottom end of the multi-year range of 4%-6% [36] - Management acknowledged challenges in developed markets but emphasized the strength of their portfolio and execution [38] Other Important Information - Free cash flow for the year was EUR 5.9 billion, representing 100% cash conversion [29] - The company has delivered more than EUR 670 million of savings from its productivity program, ahead of schedule [27][59] - The company plans to continue investing in brand and marketing, with 16.1% of turnover allocated to these areas, the highest percentage in over a decade [27] Q&A Session Questions and Answers Question: Emerging market outlook for 2026 - Management expressed confidence in emerging markets, noting improvements in India and Indonesia, and a gradual recovery in China [51][52][53] Question: Pricing outlook for 2026 - Management expects pricing growth to be around 2% for 2026, with some increased promotional spending noted [64] Question: Key building blocks for margin improvement in 2026 - Management highlighted the importance of gross margin expansion, productivity savings, and disciplined pricing as key factors for margin improvement [66][68]

Financial Data and Key Metrics Changes - For the full year, underlying sales growth was 3.5%, with volumes at 1.5% and price at 2% [5] - Turnover for the full year was EUR 50.5 billion, down 3.8% versus the prior year, primarily due to significant currency headwinds [25] - Underlying operating margin expanded by 60 basis points to 20% in 2025, reflecting a structurally strong margin profile [26] - Underlying EPS rose to EUR 3.08, up 0.7% versus the prior year, with sales growth and margin expansion contributing 6.5% to EPS growth [28] Business Line Data and Key Metrics Changes - Beauty and Wellbeing delivered underlying sales growth of 4.3%, evenly split between volume of 2.2% and price at 2.1% [10] - Personal Care delivered underlying sales growth of 4.7% for the full year, with price contributing 3.6% and volumes growing 1.1% [11] - Home Care delivered underlying sales growth of 2.6% for the year, primarily volume-led at 2.2% [14] - Foods delivered underlying sales growth of 2.5% for the year, with 0.8% from volume and 1.7% from price [16] Market Data and Key Metrics Changes - Developed markets delivered underlying sales growth of 3.6% for the year, with North America being a standout performer [19] - Emerging markets delivered underlying sales growth of 3.5% for the year, accelerating to 5.8% in the fourth quarter [21] - In India, underlying sales grew 4% for the year, with volumes up 3% [22] - In China, underlying sales growth was flat for the year, but improved in the second half, including mid-single-digit growth in the fourth quarter [23] Company Strategy and Development Direction - The company aims to sharpen its portfolio, having rotated 15% of the total portfolio in 2025 through acquisitions and disposals [3] - Focus remains on beauty, wellbeing, and personal care, with an emphasis on premium segments and digitally native brands [34] - The company is committed to a disciplined capital allocation strategy, prioritizing growth and productivity while delivering attractive capital returns [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in emerging markets, expecting volume growth of at least 2% in 2026 [36] - The company anticipates underlying sales growth for the full year to be at the bottom end of the multi-year range of 4%-6% [36] - Management highlighted the importance of maintaining a focus on volume-led growth and margin expansion [43] Other Important Information - Free cash flow for the year was EUR 5.9 billion, representing 100% cash conversion [29] - The company completed an eight-for-nine share consolidation in December 2025 following the ice cream separation [29] - The productivity program has delivered more than EUR 670 million of savings, with a commitment to complete EUR 800 million by 2026 [27][59] Q&A Session Questions and Answers Question: Emerging market outlook for 2026 - Management expressed confidence in emerging markets, noting improvements in India and Indonesia, and a gradual recovery in China [51][52][53][54] Question: Pricing outlook for 2026 - Management expects pricing growth to be around 2% for 2026, with some increased promotional spending noted [62][64] Question: Key building blocks for margin improvement in 2026 - Management highlighted a structurally high gross margin and ongoing productivity initiatives as key factors supporting margin improvement [66][68]

Core Viewpoint - The Fidelity MSCI Consumer Staples Index ETF (FSTA) and the Invesco S&P 500 Equal Weight Consumer Staples ETF (RSPS) offer different strategies for investors seeking exposure to U.S. consumer staples stocks, focusing on cost, returns, risk, and portfolio composition [1][2]. Cost and Size - FSTA has a lower expense ratio of 0.08% compared to RSPS's 0.40%, making it more cost-effective for investors [3] - FSTA has a larger asset under management (AUM) of $1.4 billion, while RSPS has $250 million [3] - The one-year return for RSPS is 12.60%, outperforming FSTA's 8.73% [3] - RSPS offers a higher dividend yield of 2.63% compared to FSTA's 2.18% [3] Performance and Risk Comparison - Over five years, RSPS experienced a maximum drawdown of -18.61%, while FSTA had a drawdown of -16.57% [4] - An investment of $1,000 would grow to $1,081 in RSPS and $1,380 in FSTA over the same period, indicating FSTA's superior growth [4] Portfolio Composition - FSTA tracks the MSCI USA IMI Consumer Staples 25/50 Index and holds 96 stocks, with top holdings like Costco Wholesale, Walmart, and Procter & Gamble making up over one-third of the fund [5] - RSPS allocates equal weight to 36 S&P 500 consumer staples stocks, reducing single-stock risk but increasing exposure to mid-cap names compared to FSTA's large-cap focus [6] Implications for Investors - FSTA's heavy reliance on major industry players may lead to higher long-term returns if these stocks perform well, but it also poses a risk during downturns [7][8] - RSPS's equal-weight strategy mitigates single-stock risk but may limit potential earnings when strong stocks are weighted equally with weaker ones [9] - The fee structure indicates that investors in FSTA would pay $8 annually for every $10,000 invested, compared to $40 for RSPS, which could accumulate to significant savings for long-term investors [9]

The State Street Consumer Staples Select Sector SPDR ETF (NYSEMKT:XLP) and the Invesco Food & Beverage ETF (NYSEMKT:PBJ) both target the U.S. consumer sector, but XLP offers broader staples exposure at a lower cost and higher yield, while PBJ focuses on food and beverage with a more diversified sector mix and higher trading friction. XLP and PBJ both give investors access to U.S. companies in food, beverage, and consumer defensive industries, but their approaches and underlying holdings differ. This comp ...

The trading week is about to serve up a heavy dose of consumer reality with a trio of earnings reports from the titans of fast food, consumer staples, and beverages. McDonald’s (MCD), Kraft Heinz (KHC), and Anheuser-Busch InBev (BUD) are all scheduled to report within a tight window starting early Wednesday, Feb. 11, providing a comprehensive look at how the American consumer is handling the high-cost economy of 2026. This cluster of reports functions like a post-Super Bowl feast for analysts, revealing ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Spotify.Getty Images Good morning! Here's the latest in trending:Tech earnings: AMD (AMD) shares are falling despite results and outlook topping estimates. Alphabet (GOOGL) and Qualcomm (QCOM) due later today.On the Hill: The House passed legislation to fund most of the government for the rest of the fiscal year, ending the four-day partial shutdown.Tensions simmer: The U.S. Navy shot down an ...

Group 1 - The Procter & Gamble Company (NYSE:PG) shares have decreased by 10% over the past year but have increased by 5.7% year-to-date [2] - Barclays raised the share price target for Procter & Gamble to $155 from $151 while maintaining an Equal Weight rating, citing pressures from oil and currency as potential headwinds in 2026 [2] - UBS lowered its share price target for Procter & Gamble to $161 from $176 but kept a Buy rating, reflecting concerns over uncertain market conditions for consumer staples stocks in late 2026 [2] - JPMorgan expressed optimism about Procter & Gamble, suggesting that the company could see sales growth acceleration and improved margins [2] - Jim Cramer supports the positive outlook from JPMorgan, highlighting the potential impact of the new CEO on the company's performance [3] Group 2 - The new CEO of Procter & Gamble is described as having an international orientation, discussing markets such as Brazil, Mexico, and China, which indicates a shift in the company's focus [3] - There is a belief that while Procter & Gamble has investment potential, certain AI stocks may offer higher returns with limited downside risk [4]

Company Overview - The Procter & Gamble Company (NYSE:PG) is one of the largest consumer goods companies globally [2] - The company's shares have decreased by over 11% in the past year but have increased by 5.4% year-to-date [2] Analyst Ratings and Price Targets - UBS reduced its share price target for Procter & Gamble to $161 from $176 while maintaining a Buy rating [2] - Barclays raised its price target to $155 from $151 and kept an Equal Weight rating, citing potential challenges from oil and currency pressures [2] Financial Performance - Procter & Gamble reported revenue of $22.21 billion, which fell short of analyst expectations of $22.28 billion [2] - The CEO indicated that the company expects to maintain its profit and sales guidance despite the revenue miss [2] Market Sentiment and Commentary - Jim Cramer noted that the company had preannounced its poor performance multiple times, leading to a significant drop in stock price upon earnings release [3] - Cramer suggested that the strategy of preannouncing poor results could be a tactic to manage market expectations [3]

Core Insights - Procter & Gamble (P&G) has seen its stock increase over 10,000% since the 1980s, but it has struggled to attract market attention recently [1] - The company's recent quarterly earnings are not expected to significantly change its market status, with geopolitical factors influencing investor behavior [2] Business Backdrop - Over the past decade, P&G has focused on a tighter portfolio of essential brands, moving away from food and smaller brands, which has allowed it to outperform competitors like Unilever [4] - Growth is now more reliant on pricing, product mix, and cost control rather than volume gains from innovation, making the company vulnerable in a tightening consumer environment [5] Quarterly Performance - For the quarter ending December 31, P&G reported $22.2 billion in sales, a 1% increase from the previous year, but organic sales remained flat due to a 1% drop in volume [6] - The decline in volume affected various segments, with Baby, Feminine, and Family Care seeing a 4% drop in organic sales, while Health Care and Beauty performed better due to premium products [7] Margin Pressures - Tariffs have significantly impacted P&G's margins, with an expected $400 million in after-tax tariff costs for fiscal 2026, leading to a 60 basis point decline in margins [8]

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for failing to disclose significant issues in its infant formula business, leading to overstated financial results and subsequent stock price decline [2][8]. Allegation Details - The lawsuit alleges that Perrigo did not disclose: 1. Significant underinvestment in maintenance and operational improvements in the infant formula business acquired from Nestlé [8]. 2. The need for substantial capital and operational expenditures beyond previously stated estimates to remediate the infant formula business [8]. 3. Significant manufacturing deficiencies in the infant formula facility [8]. 4. The impact of these issues resulted in overstated financial results, including earnings and cash flow [8]. Financial Impact - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a reduction in its fiscal year 2025 outlook primarily due to challenges in the infant formula industry [8]. - Following this announcement, Perrigo's stock price fell by $5.09, or 25.2%, closing at $15.10 per share on the same day [8].